logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9023402 B1

PDFFull Text
Date of Patent:
May. 05, 2015

Filed:

Apr. 01, 2011

Method for treating a mammal by administration of a compound having the ability to release co

Applicants:

Werner E. Haas, Oeiras, PT;

Carlos C. Romao, Cascias, PT;

Beatriz Royo, Oeiras, PT;

Ana Cristina Fernandes, Amadora, PT;

Isabel Goncalves, Frente, PT;

Inventors:

Werner E. Haas, Oeiras, PT;

Carlos C. Romao, Cascias, PT;

Beatriz Royo, Oeiras, PT;

Ana Cristina Fernandes, Amadora, PT;

Isabel Goncalves, Frente, PT;

Assignee:

ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda., Oeiras, PT;

Attorney:

Wolf, Greenfield & Sacks, P.C.

Primary Examiner:

John Pak

Int. Cl.
CPC ...
A61K 33/00 (2006.01); A61K 33/24 (2006.01); A61K 31/28 (2006.01); A61K 31/665 (2006.01); A61K 31/67 (2006.01); A61K 31/675 (2006.01); C07F 17/00 (2006.01); A61K 31/00 (2006.01); A61K 31/555 (2006.01); A61K 31/60 (2006.01); A61K 31/603 (2006.01); A61K 31/616 (2006.01); A61K 31/695 (2006.01); A61K 31/7048 (2006.01); A61K 31/7135 (2006.01); A61K 33/14 (2006.01); A61K 33/32 (2006.01); A61K 45/06 (2006.01); A61K 47/48 (2006.01); C07F 11/00 (2006.01); C07F 13/00 (2006.01); C07F 15/02 (2006.01);
U.S. Cl.
CPC ...
C07F 17/00 (2013.01); A61K 31/00 (2013.01); A61K 31/28 (2013.01); A61K 31/555 (2013.01); A61K 31/60 (2013.01); A61K 31/603 (2013.01); A61K 31/616 (2013.01); A61K 31/695 (2013.01); A61K 31/7048 (2013.01); A61K 31/7135 (2013.01); A61K 33/00 (2013.01); A61K 33/14 (2013.01); A61K 33/32 (2013.01); A61K 45/06 (2013.01); A61K 47/48015 (2013.01); C07F 11/005 (2013.01); C07F 13/005 (2013.01); C07F 15/02 (2013.01); Y10S 514/825 (2013.01); Y10S 514/929 (2013.01); Y10S 514/826 (2013.01); Y10S 514/887 (2013.01); Y10S 514/894 (2013.01); Y10S 514/903 (2013.01); Y10S 514/886 (2013.01); Y10S 514/824 (2013.01); Y10S 514/879 (2013.01); Y10S 514/959 (2013.01); Y10S 514/964 (2013.01); Y10S 514/921 (2013.01); Y10S 514/958 (2013.01); Y10S 514/95 (2013.01);
Abstract

Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.

Find Patent Forward Citations

Loading…